456
Participants
Start Date
November 30, 2002
Primary Completion Date
September 30, 2006
Study Completion Date
September 30, 2006
exenatide
subcutaneous injection, 5 mcg, twice a day for 4 weeks (transition period), then 10 mcg twice a day till study termination
Research Site, Birmingham
Research Site, Anaheim
Research Site, Bellflower
Research Site, Burlingame
Research Site, Chula Vista
Research Site, Concord
Research Site, Encino
Research Site, Fremont
Research Site, La Jolla
Research Site, Los Gatos
Research Site, Moreno Valley
Research Site, Redwood City
Research Site, San Mateo
Research Site, Walnut Creek
Research Site, Aurora
Research Site, Denver
Research Site, Gainesville
Research Site, Jacksonville
Research Site, Largo
Research Site, Maitland
Research Site, Miami
Research Site, Ocala
Research Site, Blairsville
Research Site, Honolulu
Research Site, Chicago
Research Site, Indianapolis
Research Site, Lexington
Research Site, Covington
Research Site, New Orleans
Research Site, Slidell
Research Site, Detroit
Research Site, Edina
Research Site, Minneapolis
Research Site, Gulfport
Research Site, Picayune
Research Site, Chesterfield
Research Site, St Louis
Research Site, Butte
Research Site, Las Vegas
Research Site, New York
Research Site, Rochester
Research Site, Cary
Research Site, Durham
Research Site, Columbus
Research Site, Marion
Research Site, Maumee
Research Site, Mentor
Research Site, Clinton
Research Site, Oklahoma City
Research Site, Medford
Research Site, Portland
Research Site, Camp Hill
Research Site, Philadelphia
Research Site, Dallas
Research Site, Houston
Research Site, Midland
Research Site, San Antonio
Research Site, Salt Lake City
Research Site, Olympia
Research Site, Spokane
Lead Sponsor
AstraZeneca
INDUSTRY